Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells

[1]  Matthew J. Frigault,et al.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events , 2020, Journal for ImmunoTherapy of Cancer.

[2]  Jahir M. Gutierrez,et al.  Cardiovascular Events Associated with Chimeric Antigen Receptor T (CAR-T) Therapy: Cross-Sectional FAERS Analysis: Cardiovascular Events with CAR-T Therapy. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  C. Mackall,et al.  Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies , 2020, Journal for ImmunoTherapy of Cancer.

[4]  S. Rives,et al.  Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia , 2020, Bone Marrow Transplantation.

[5]  M. Perales,et al.  Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. , 2020, Blood advances.

[6]  L. Fayad,et al.  Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma , 2020, Haematologica.

[7]  Michael R. Green,et al.  Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. , 2020, Blood advances.

[8]  M. Perales,et al.  DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. , 2020, Blood advances.

[9]  S. Seo,et al.  How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies. , 2020, Blood.

[10]  A. S. Li,et al.  CAR T-Cell Therapy Associated Ocular Adverse Events Reported to the Food and Drug Administration , 2020 .

[11]  Ying Xiao,et al.  Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma. , 2020, International journal of radiation oncology, biology, physics.

[12]  S. Grupp,et al.  CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). , 2020, Journal of Clinical Oncology.

[13]  M. Oberley,et al.  Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. , 2020, Blood advances.

[14]  J. Pinilla-Ibarz,et al.  Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma , 2020, Haematologica.

[15]  Sameer S. Kadri,et al.  The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. , 2020, Journal of critical care.

[16]  S. Steinberg,et al.  CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Englund,et al.  Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults , 2020, Open forum infectious diseases.

[18]  K. Ness,et al.  Patient-Reported Outcomes in Survivors of Childhood Hematologic Malignancies with Hematopoietic Stem Cell Transplant. , 2020, Blood.

[19]  Angela Steineck,et al.  Psychosocial care for children receiving chimeric antigen receptor (CAR) T‐cell therapy , 2020, Pediatric blood & cancer.

[20]  M. Perales,et al.  Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy , 2020, British journal of haematology.

[21]  M. Perales,et al.  Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  G. Salles,et al.  Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. , 2020, Blood advances.

[23]  Aloísio Santos,et al.  Systematic Literature Review , 2020, Literature Reviews.

[24]  Matthew J. Frigault,et al.  Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  Jonathan M. Hernandez,et al.  Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report , 2020, Pediatric transplantation.

[26]  Depei Wu,et al.  Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden , 2020, Journal of immunotherapy.

[27]  M. Bar,et al.  Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  M. Bar,et al.  Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor-T Cell Therapy. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  David A. Williams,et al.  Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. , 2019, Blood.

[30]  S. Grupp,et al.  Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Grupp,et al.  Subcutaneous immunoglobulin replacement following CD19‐specific chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia in pediatric patients , 2019, Pediatric blood & cancer.

[32]  Aaron D. Falchook,et al.  Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. , 2019, International journal of radiation oncology, biology, physics.

[33]  K. Davis,et al.  Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[34]  Jennifer E Liu,et al.  Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives. , 2019, Journal of the American College of Cardiology.

[35]  Dae Hyun Lee,et al.  Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). , 2019, Journal of the American College of Cardiology.

[36]  M. Bar,et al.  Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. , 2019, Blood advances.

[37]  A. Dispenzieri,et al.  Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life , 2019, Blood.

[38]  M. Jensen,et al.  Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo , 2019, Blood.

[39]  S. Tosi,et al.  MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy? , 2019, Cells.

[40]  M. Jensen,et al.  Preemptive Mitigation of CD19 CAR T Cell Cytokine Release Syndrome Without Attenuation of Anti-Leukemic Efficacy. , 2019, Blood.

[41]  Matthew R. Gazzara,et al.  Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 , 2019, Leukemia.

[42]  H. Kotani,et al.  Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy , 2019, British journal of haematology.

[43]  M. Raffeld,et al.  Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. , 2019, Blood advances.

[44]  R. Hevner,et al.  Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy , 2019, Annals of neurology.

[45]  S. Rives,et al.  Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel , 2019, Clinical Trials.

[46]  S. Forman,et al.  MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA , 2019, Hematological Oncology.

[47]  S. Sidana,et al.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  D. Maloney,et al.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. , 2019, Blood.

[49]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  C. Callahan,et al.  Pediatric Survivorship: Considerations following CAR T‐cell therapy , 2019, Clinical journal of oncology nursing.

[51]  J. Kochenderfer,et al.  Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. , 2019, Blood reviews.

[52]  C. Mackall,et al.  Pharmacologic control of CAR-T cell function using dasatinib. , 2019, Blood advances.

[53]  J. Schachter,et al.  Early and late hematologic toxicity following CD19 CAR-T cells , 2019, Bone Marrow Transplantation.

[54]  Aaron J. Johnson,et al.  GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. , 2019, Blood.

[55]  M. Labopin,et al.  Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients , 2019, JAMA oncology.

[56]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[57]  Katie S. Gatwood,et al.  American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  I. Flinn,et al.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.

[59]  P. Veys,et al.  Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study , 2018, Blood.

[60]  M. Jensen,et al.  Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission , 2018, Blood.

[61]  Amanda M Li,et al.  Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia , 2018, Blood.

[62]  M. Jensen,et al.  Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia , 2018, Blood.

[63]  K. Davis,et al.  Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL) , 2018, Blood.

[64]  M. Sadelain,et al.  Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  C. Turtle,et al.  Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies , 2018, CNS Drugs.

[66]  Hans Bitter,et al.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia , 2018, Nature Medicine.

[67]  D. Teachey,et al.  Neurotoxicity after CTL019 in a pediatric and young adult cohort , 2018, Annals of neurology.

[68]  T. Fry,et al.  Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy , 2018, Journal of immunotherapy.

[69]  M. Oberley,et al.  Myeloid lineage switch following chimeric antigen receptor T‐cell therapy in a patient with TCF3‐ZNF384 fusion‐positive B‐lymphoblastic leukemia , 2018, Pediatric blood & cancer.

[70]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[71]  K. Cornetta,et al.  Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience , 2018, Molecular therapy. Methods & clinical development.

[72]  S. Grupp,et al.  CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic Reticulum , 2018, Molecular and Cellular Biology.

[73]  K. Rezvani,et al.  Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy , 2018, Nature Reviews Clinical Oncology.

[74]  H. Griffis,et al.  Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[75]  K. King,et al.  The Role of Interferon-Gamma in Hematopoietic Stem Cell Development, Homeostasis, and Disease , 2018, Current Stem Cell Reports.

[76]  S. Nikiforow,et al.  Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema , 2018, Journal of neuropathology and experimental neurology.

[77]  D. Reinhardt,et al.  Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. , 2018, Blood advances.

[78]  L. Deangelis,et al.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.

[79]  P. Kluetz,et al.  Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. , 2018, The Lancet. Oncology.

[80]  Chris Feudtner,et al.  Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next , 2018, The Patient - Patient-Centered Outcomes Research.

[81]  M. Sulis,et al.  Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study , 2018, Leukemia.

[82]  K. Jhaveri,et al.  Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[83]  T. Fry,et al.  Efficacy and Kinetics of CAR-T Cell Therapy in Children and Young Adults with Extramedullary Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) , 2018 .

[84]  S. Seo,et al.  Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  P. Hwu,et al.  Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' , 2018, Nature Reviews Clinical Oncology.

[86]  D. Teachey,et al.  Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' , 2018, Nature Reviews Clinical Oncology.

[87]  P. Hinds,et al.  Child and adolescent self-report symptom measurement in pediatric oncology research: a systematic literature review , 2018, Quality of Life Research.

[88]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[89]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[90]  J. Tolar,et al.  Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T , 2018, International journal of molecular sciences.

[91]  K. Cornetta,et al.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[92]  M. Ebinger,et al.  CD34+ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation , 2018, British journal of haematology.

[93]  L. Minasian,et al.  Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections , 2017, Clinical Cancer Research.

[94]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[95]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[96]  Amanda M Li,et al.  Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia , 2017 .

[97]  J. Rossi,et al.  Marked Re-Expansion of Chimeric Antigen Receptor (CAR) T Cells and Tumor Regression Following Nivolumab Treatment in a Patient Treated with Axicabtagene Ciloleucel (axi-cel; KTE-C19) for Refractory Diffuse Large B Cell Lymphoma (DLBCL) , 2017 .

[98]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[99]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[100]  Daniel Li,et al.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.

[101]  D. Dimitrov,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[102]  S. Rosenberg,et al.  Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[103]  D. Maloney,et al.  Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. , 2017, Blood.

[104]  Lisa Rosenbaum.  Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. , 2017, The New England journal of medicine.

[105]  Dong Chen,et al.  Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis , 2017, Blood Cancer Journal.

[106]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[107]  G. Escherich,et al.  Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement , 2017, Pediatric blood & cancer.

[108]  Bruce L Levine,et al.  PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. , 2017, Blood.

[109]  S. Rosenberg,et al.  Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation , 2016 .

[110]  M. Grootenhuis,et al.  Healthcare Professionals’ Preferences and Perceived Barriers for Routine Assessment of Patient‐Reported Outcomes in Pediatric Oncology Practice: Moving Toward International Processes of Change , 2016, Pediatric blood & cancer.

[111]  S. Grupp,et al.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. , 2016, The Journal of clinical investigation.

[112]  Y. T. Cheung,et al.  Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. , 2016, The Lancet. Haematology.

[113]  G. Reaman,et al.  Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine Workshop highlights and next steps , 2016, CA: a cancer journal for clinicians.

[114]  G. Wertheim,et al.  Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. , 2016, Blood.

[115]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[116]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[117]  R. Mcmasters,et al.  Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy , 2016, Pediatric blood & cancer.

[118]  D. Maloney,et al.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.

[119]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[120]  M. Grootenhuis,et al.  Psychosocial Assessment as a Standard of Care in Pediatric Cancer , 2015, Pediatric blood & cancer.

[121]  L. Kanz,et al.  Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation , 2015, Journal of Cancer Research and Clinical Oncology.

[122]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[123]  Y. T. Cheung,et al.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review , 2015, Neuroscience & Biobehavioral Reviews.

[124]  S. Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[125]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[126]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[127]  S. Raimondi,et al.  Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[129]  R. Escorpizo,et al.  Challenges and Opportunities , 1999, Deep Eutectic Solvents for Pretreatment of Lignocellulosic Biomass.

[130]  Marian Kelley,et al.  One size does not fit all. , 2011, Bioanalysis.

[131]  R. Ganetzky,et al.  Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes , 2010, Haematologica.

[132]  S. Corey,et al.  Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid Leukemia: The MD Anderson Cancer Center Experience , 2009, Journal of pediatric hematology/oncology.

[133]  Katherine N. Lemon,et al.  The Reinforcing Effects of Loyalty Program Partnerships and Core Service Usage , 2009 .

[134]  D. Kuter.  Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. , 2009, Annual review of medicine.

[135]  Sa A. Wang,et al.  Hemophagocytosis exacerbated by G‐CSF/GM‐CSF treatment in a patient with myelodysplasia , 2004, American journal of hematology.

[136]  P. Murray,et al.  Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role , 2004, Eye.

[137]  R. Mulhern,et al.  ReviewNeurocognitive sequelae of childhood cancers and their treatment , 2004 .

[138]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[139]  M. Perales,et al.  Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[140]  P. Sorensen,et al.  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. , 2015, Blood.

[141]  R. Mulhern,et al.  Neurocognitive sequelae of childhood cancers and their treatment. , 2004, Pediatric rehabilitation.

[142]  L. McDonald,et al.  Vancomycin intermediate and resistant Staphylococcus aureus. What the nephrologist needs to know. , 2004, Nephrology news & issues.

[143]  D. C. Henckel,et al.  Case report. , 1995, Journal.